Physician profile
Michael S Halpin
NPI 1376545590
$952.69
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $207 · 2021: $278 · 2022: $210.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $230.85 | 2019-2022 | |
| Abbvie INC. | $139.94 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $135.64 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $135.27 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $90.66 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $77.25 | 2019-2020 | |
| Lombart Brothers, INC. | $27.44 | 2019-2020 | |
| Shire North American Group INC | $18.61 | 2019 | |
| Horizon Therapeutics Plc | $17.41 | 2021 | |
| Bausch & Lomb Americas INC. | $16.91 | 2022 | |
| Sight Sciences, INC. | $14.54 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.12 | 2022 | |
| Dompe US, INC. | $12.97 | 2021 | |
| Mallinckrodt Hospital Products INC. | $11.68 | 2020 | |
| Biotissue Holdings INC. | $10.40 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Halpin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.